HBW-016-K / Hyperway Pharma - LARVOL DELTA

HBW-016-K, a novel orally available pan-KRAS inhibitor targeting both "ON" and "OFF" states, is potent, selective, efficacious, safe, and high tissue-penetrant (AACR 2025) - "HBW-016-K is a promising novel pan-KRAS inhibitor with superior potency, selectivity, and efficacy. Its favorable PK profile and safety profile support its advancement into clinical development. HBW-016-K has the potential to significantly impact the treatment of KRAS-driven cancers, particularly those with limited therapeutic options, such as lung, colorectal, and pancreatic cancer."

Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • HRAS • KRAS